Advanced in Venous Thromboembolism (VTE)

Dr. Susan H. Tannenbaum

Hematology Oncology | Oncology | Hematology
University Of Connecticut Health Center
263 Farmington Ave, 
Farmington, CT 
Advanced in Venous Thromboembolism (VTE)
University Of Connecticut Health Center
263 Farmington Ave, 
Farmington, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Susan Tannenbaum is a Hematologist Oncology specialist and an Oncologist in Farmington, Connecticut. Dr. Tannenbaum is rated as an Advanced provider by MediFind in the treatment of Venous Thromboembolism (VTE). Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Lung Cancer, and Inflammatory Breast Cancer.

Her clinical research consists of co-authoring 22 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in CT
Hospital Affiliations
John Dempsey Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

UNIVERSITY OF CONNECTICUT HEALTH CENTER
263 Farmington Ave, Farmington, CT 06030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: ONC-392, Pembrolizumab
Study Phase: Phase 1/Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase I Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma
A Phase I Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma
Enrollment Status: Terminated
Publish Date: November 07, 2022
Intervention Type: Biological
Study Phase: Phase 1
Phase II Trial of Abemaciclib and T-DM1 in Women and Men With HER2-positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment With a Taxane, Trastuzumab and Pertuzumab
Phase II Trial of Abemaciclib and T-DM1 in Women and Men With HER2-positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment With a Taxane, Trastuzumab and Pertuzumab
Enrollment Status: Withdrawn
Publish Date: May 26, 2022
Intervention Type: Drug, Biological
Study Drugs: Abemaciclib, Trastuzumab Emtansine
Study Phase: Phase 2
Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors: Systemic Impact Versus Local Objective Benefits and Quality of Life
Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors: Systemic Impact Versus Local Objective Benefits and Quality of Life
Enrollment Status: Completed
Publish Date: September 18, 2017
Intervention Type: Behavioral
Study Phase: Not Applicable
View 5 Less Clinical Trials

22 Total Publications

Racial Disparities in Pathologic Complete Response and Survival after Neoadjuvant Chemotherapy for Breast Cancer.
Racial Disparities in Pathologic Complete Response and Survival after Neoadjuvant Chemotherapy for Breast Cancer.
Journal: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Published: April 11, 2025
Similar Doctors
Elite in Venous Thromboembolism (VTE)
Dr. Alfred I. Lee
Hematology | Oncology
Elite in Venous Thromboembolism (VTE)
Dr. Alfred I. Lee
Hematology | Oncology

Yale University

800 Howard Ave, 
New Haven, CT 
 (30.6 miles away)
203-785-2140
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alfred Lee is a Hematologist and an Oncologist in New Haven, Connecticut. Dr. Lee is rated as a Distinguished provider by MediFind in the treatment of Venous Thromboembolism (VTE). His top areas of expertise are Venous Thromboembolism (VTE), Shwartzman Phenomenon, Antiphospholipid Syndrome, Splenectomy, and Bone Marrow Aspiration.

Advanced in Venous Thromboembolism (VTE)
Dr. Driola Brahaj
Hematology Oncology | Hematology | Oncology
Advanced in Venous Thromboembolism (VTE)
Dr. Driola Brahaj
Hematology Oncology | Hematology | Oncology

Bristol Hospital Multi-Specialty Group, Inc.

41 Brewster Rd, 
Bristol, CT 
 (8.2 miles away)
860-585-3000
Languages Spoken:
English
See accepted insurances

Driola Brahaj is a Hematologist Oncology specialist and a Hematologist in Bristol, Connecticut. Dr. Brahaj is rated as a Distinguished provider by MediFind in the treatment of Venous Thromboembolism (VTE). Her top areas of expertise are Small Cell Lung Cancer (SCLC), Inflammatory Breast Cancer, Lung Cancer, and Pleuropulmonary Blastoma.

Advanced in Venous Thromboembolism (VTE)
Dr. Paul E. Zorsky
Hematology Oncology | Hematology | Oncology
Advanced in Venous Thromboembolism (VTE)
Dr. Paul E. Zorsky
Hematology Oncology | Hematology | Oncology

Trinity Health Of New England Provider Network Organization Inc

114 Woodland St, 
Hartford, CT 
 (5.8 miles away)
860-714-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Paul Zorsky is a Hematologist Oncology specialist and a Hematologist in Hartford, Connecticut. Dr. Zorsky is rated as an Advanced provider by MediFind in the treatment of Venous Thromboembolism (VTE). His top areas of expertise are Lung Cancer, Chronic Lymphocytic Leukemia (CLL), Familial Colorectal Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Zorsky is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tannenbaum's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 51 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile